🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Simultaneous Bilateral Radiofrequency Thalamotomy for Medication-Refractory Essential Tremor

RecruitingNAAges 20 Years - 70 YearsAllTokyo Women's Medical University
NCT07066358 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate the safety and effectiveness of simultaneous bilateral radiofrequency thalamotomy for patients with medication-refractory essential tremor (ET). Essential tremor is a common neurological condition that causes involuntary shaking, often affecting the hands and interfering with daily activities such as writing, eating, or using tools. While medications such as propranolol and primidone can help some patients, others experience limited or no benefit. In this study, five adult participants diagnosed with essential tremor that does not respond to standard medications will undergo simultaneous bilateral stereotactic radiofrequency lesioning of the ventral intermediate nucleus (Vim) of the thalamus. This procedure involves precisely targeting both sides of the Vim to reduce tremor in both arms during a single surgical session. Prior to surgery, participants will un

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged 20 to 70 years. * Diagnosis of essential tremor by a neurologist or neurosurgeon specializing in movement disorders. * Refractory to standard pharmacological therapy (e.g., propranolol, primidone, benzodiazepines, or alprenolol). * Mini-Mental State Examination (MMSE) score ≥ 27. * Able to undergo MRI. * Provided written informed consent for participation in the study. Exclusion Criteria: * History or evidence of bleeding tendency. * MRI contraindications (e.g., metallic implants, severe claustrophobia). * Presence of intracranial pathology on preoperative MRI that would interfere with surgery. * Pregnant or breastfeeding individuals. * Any other condition that the principal investigator deems inappropriate for study participation.
💊

What it tests

  • Simultaneous Bilateral RF Thalamotomy
📍

Where

1 site
Tokyo Women's Medical University, Department of Neurosurgery
Shinjuku-Ku, Japan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy